

Kalydeco® (ivacaftor) - Expanded indication

- On August 15, 2018, <u>Vertex announced</u> the FDA approval of <u>Kalydeco (ivacaftor)</u> for the treatment
 of cystic fibrosis (CF) in patients age 12 months and older who have one mutation in the cystic
 fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor
 potentiation based on clinical and/or in vitro assay data.
 - Previously, Kalydeco was approved for use in patients ≥ 2 years of age for this indication.
 - If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.
- The efficacy of Kalydeco in patients 12 months to < 24 months was extrapolated from patients ≥ 6 years of age with support from population pharmacokinetic analyses showing similar drug exposure levels in adults and children 12 months to < 24 months of age.
- Safety of Kalydeco in patients aged 12 to < 24 months was derived from a cohort of 19 patients of
 this age range in a clinical study and administered either 50 mg or 75 mg of Kalydeco granules twice
 daily. The safety profile of patients in this trial is similar to that observed in patients ≥ 2 years of age.
- The dose of Kalydeco for pediatric patients 12 months to less than 6 years of age is weight based. Each dose should be administered just before or just after fat-containing food.

Body weight (kg)	Dosage Regimen	Total Daily Dose
7 kg to < 14 kg	One 50 mg packet every 12 hours	100 mg/day
≥ 14 kg	One 75 mg packet every 12 hours	150 mg/day

• The recommended dose of Kalydeco for adults and pediatric patients age ≥ 6 years of age is one 150 mg tablet taken orally every 12 hours with fat-containing food.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.